Glucocorticoid receptor antagonism reverts docetaxel resistance in human prostate cancer

Glucocorticoid receptor antagonism reverts docetaxel resistance in human prostate cancer

Resistance to docetaxel is a major clinical problem in advanced prostate cancer (PCa). Although glucocorticoids (GCs) are frequently used in combination with docetaxel, it is unclear to what extent GCs and their receptor, the glucocorticoid receptor (GR), contribute to the chemotherapy resistance. I...

Full description

Bibliographic Details
Main Authors: Kroon, Jan, Puhr, Martin, Buijs, Jeroen T, van der Horst, Geertje, Hemmer, Daniëlle M, Marijt, Koen A, Hwang, Ming S, Masood, Motasim, Grimm, Stefan, Storm, Gert, Metselaar, Josbert M, Meijer, Onno C, Culig, Zoran, van der Pluijm, Gabri
Format: Online
Language:English
Published: Bioscientifica Ltd 2016
Online Access:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4657186/

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4657186/

Similar Items